exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274847 RNA Name: hsa-miR-493-3p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 100869116 End Site(bp): 100869137 External Links: hsa-miR-493-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ANKS1A chr6 34889255 35091406 + ASF1B chr19 14119512 14136613 - BACH2 chr6 89926528 90296908 - BRPF3 chr6 36196744 36232790 + C17orf49 chr17 7014495 7017525 + DYNLRB1 chr20 34516409 34540958 + EPG5 chr18 45847609 45967329 - HIF1AN chr10 100529072 100559998 + MEX3A chr1 156072013 156082465 - MFN2 chr1 11980181 12013514 + MMGT1 chrX 135962070 135974063 - MTUS1 chr8 17643795 17800917 - NPTX1 chr17 80466834 80477843 - PRKAR2A chr3 48744597 48847874 - PXN chr12 120210439 120265771 - RNASEK-C17orf49 chr17 7012635 7017520 + XPO6 chr16 28097979 28211920 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016831.1 chr7 130876809 130913310 - AC016876.2 chr17 7581964 7584086 - AC022167.2 chr16 8848105 8860456 + AC144548.1 chr12 110387463 110445548 - AL359924.1 chr1 237862175 237928321 + MIR200CHG chr12 6963246 6964447 + TUG1 chr22 30969245 30979395 + Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.